Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.